Original Investigations: Pathogenesis and Treatment of Kidney Disease and HypertensionRelationship of renal function to homocysteine and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment*,**
Section snippets
Subjects and methods
One hundred ninety-seven patients (age range, 27.2 to 86.1 years) with renal impairment (plasma creatinine level, 1.08 to 11.68 mg/dL [96 to 1,033 μmol/L]) were studied, although none had started renal replacement therapy yet. The cause of renal impairment was diabetes mellitus in 30%, hypertensive nephropathy in 13%, chronic glomerulonephritis in 13%, adult polycystic kidney disease in 8%, renovascular in 8%, unknown in 13%, and miscellaneous in 15%. Patients administered folic acid, vitamin B
Results
Table 1 lists patient characteristics for each group of patients, divided by EDTA clearance.
Empty Cell Groups by GFR (mL/min/1.73 m2) Empty Cell <10 10-20 20-30 30-45 45-75 No. of patients 57 50 30 34 26 Age (y) 66.5 ± 12.4 64.8 ± 13.0 64.2 ± 13.7 59.5 ± 12.9 52.5 ± 14.6 Sex (M/F) 40/17 33/17 21/9 29/8 21/5 Body mass index 24.6 ± 4.1 27.8 ± 5.4 26.9 ± 4.5 27.1 ± 5.1 27.9 ± 5.4 Plasma creatinine (mg/dL) 5.61 ± 1.87 4.23 ± 1.53 2.02 ± 0.54 1.61 ± 0.27 1.39 ± 1.45 GFR (mL/min) 7.6 ± 1.5 13.5 ± 2.6 24.9 ± 3.1 37.5 ±
Discussion
This is the first study to examine both tHcy and Lp(a) levels in a large number of patients with renal impairment using reliable methods of measuring renal function that has included proteinuric patients and those with diabetic nephropathy. Our data for tHcy levels are similar to previous studies that examined tHcy levels in patients with renal impairment measured by isotopic methods.30, 31, 32, 33 In the current study, even in patients with mild renal impairment (GFR, 45 to 75 mL/min/1.73 m2),
References (55)
- et al.
Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
Kidney Int
(1999) - et al.
Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment
Am J Kidney Dis
(2001) - et al.
The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels
Atherosclerosis
(1986) - et al.
Inflammation enhances cardiovascular risk and mortality in haemodialysis patients
Kidney Int
(1999) - et al.
Lipoprotein(a) is a predictor for cardiovascular mortality of haemodialysis patients
Kidney Int
(1999) - et al.
Lipoprotein(a) as a risk factor for coronary artery disease in haemodialysis patients
Kidney Int
(1999) - et al.
Hyperhomocysteinemia, hyperfibrinogenemia and lipoprotein(a) excess in maintenance dialysis patients: A matched case-control study
Atherosclerosis
(1996) - et al.
Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: Critical impact of true glomerular filtration rate
Atherosclerosis
(2001) - et al.
Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus
Kidney Int
(1999) - et al.
Lipoprotein(a) and the risk of myocardial infarction
Atherosclerosis
(1981)
Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans
J Lipid Res
Lipoprotein(a)
Adv Clin Chem
Net uptake of plasma homocysteine by rat kidney uptake in vivo
Atherosclerosis
No net renal extraction of homocysteine in fasting humans
Kidney Int
Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation
J Lipid Res
Homocysteine and coronary atherosclerosis
J Am Coll Cardiol
Comparative mortality from cardiovascular disease in patients with chronic renal failure
Nephrol Dial Transplant
Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
J Clin Invest
Lipoprotein(a) as a predictor for myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)
Eur J Clin Invest
Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women
Arterioscler Thromb Vasc Biol
Lp(a) lipoprotein is an independent discriminating risk factor for premature peripheral atherosclerosis among white men
Arch Intern Med
Lipoprotein(a) in ischaemic cerebrovascular disease: A new approach to the assessment of stroke
Neurology
Multi-centre study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by haemodialysis or continuous ambulatory peritoneal dialysis
J Am Soc Nephrol
High serum lipoprotein(a) concentrations in uraemic patients treated with continuous ambulatory peritoneal dialysis
Clin Nephrol
Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy
Nephrol Dial Transplant
Lipoprotein(a) is an independent risk factor for cardiovascular disease in haemodialysis patients
Circulation
The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in haemodialysis patients: A prospective follow-up
J Am Soc Nephrol
Cited by (26)
Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer's disease
2022, Advanced Drug Delivery ReviewsCitation Excerpt :In the first instance, the elevation of homocysteine, a non-proteinogenic amino acid, has commonly been observed in moderate renal insufficiency and is associated with an increase in the incidence of dementia [115]. Moreover, concomitant renal insufficiency and dementia have been associated with the occurrence of anaemia, in addition to an increase in oxidative stress; both of which are implicated in dementia pathogenesis [115-118]. Neurodegenerative disorders such as AD also share common risk factors with cardiovascular disease and chronic kidney disease (CKD) [119], such as inflammation and hypertension.
Initial Clinical Encounter with the Patient with Established Hypertension
2010, Cardiology ClinicsCitation Excerpt :Emerging biomarkers of CV risk can be evaluated in select populations to justify aggressive risk modulation. Such emerging risk markers include uric acid, high-sensitivity C-reactive protein (hsCRP), and homocysteine.16,17 The presence of microalbuminuria or decreased eGFR is associated with increased CV risk18–21; similarly, increased hsCRP has been associated with increased CV risk even in patients classified as low risk by traditional measures.22,23
The elderly population on haemodialysis: evaluation, prevention and treatment of cognitive decline
2007, Nephrologie et TherapeutiqueLipoprotein (a) in patients with spontaneous venous thromboembolism
2007, Thrombosis ResearchAssociation between carotid artery intima-media thickness and cardiovascular risk factors in CKD
2005, American Journal of Kidney Diseases
- *
Address reprint requests to Darren S. Parsons, BM, BS, Department of Renal Medicine, Charing Cross Hospital, Fulham Palace Rd, London W6 8RF, UK. E-mail: [email protected]
- **
0272-6386/02/4005-0004$35.00/0